People who inject drugs (PWID) are commonly exposed to hepatitis B virus (HBV) and hepatitis D virus (HDV). We evaluated the prevalence of HDV viremia among hepatitis B surface antigen (HBsAg)-positive PWID (n = 73) using a new quantitative microarray antibody capture (Q-MAC) assay, HDV western blot, and HDV RNA. HDV Q-MAC performed well in this cohort: anti-HDV, 100% sensitivity and specificity; HDV viremia, 61.5% sensitivity and 100% specificity. Hepatitis D viremia was present in 35.6% of HBsAg-positive participants and was more common in those with resolved compared to chronic hepatitis C (5.1% vs 0.6%; adjusted odds ratio, 9.80; P < .0001).
Hepatitis D virus (HDV) requires hepatitis B virus (HBV) for its life cycle; people who inject drugs (PWID) are commonly exposed to both viruses [1] . Compared to those with HBV monoinfection, HBV-HDV coinfected individuals experience a more rapid progression to cirrhosis, higher rates of hepatocellular carcinoma, and mortality [1] [2] [3] . In the United States, PWID are the group at highest risk of acquiring and transmitting HDV, yet epidemiological data among such individuals are limited and largely based on anti-HDV measurements among individuals with chronic hepatitis B [4] [5] [6] . For clinical and public health purposes, the presence of HDV RNA is more relevant, as viremic individuals can transmit the virus and might benefit from antiviral treatment. Furthermore, the prevalence of hepatitis C virus (HCV) infection among PWID is high, therefore triple infection with chronic hepatitis viruses occurs [7, 8] and the relationship between HDV, HBV, and HCV appears to be complex [9] .
Assessment of HDV prevalence has been limited by the lack of reliable and convenient antibody assays, and varying sensitivity of reverse transcriptase polymerase chain reaction (RT-PCR) assays for HDV RNA [10] . A recently developed HDV quantitative microarray antibody capture (Q-MAC) assay showed excellent performance characteristics in a Mongolian population [10, 11] , but this assay must be evaluated in other populations. We evaluated HDV Q-MAC among PWID from San Francisco and examined the prevalence of HDV viremia in this cohort.
METHODS
As previously described [12] , the Urban Health Study (UHS) was a serial cross-sectional epidemiological study that recruited PWID from street settings in the San Francisco Bay area from 1985 through 2002; individuals included in the current analysis were evaluated between 1998 and 2000. Participants were ≥18 years of age and had injected illicit drugs within the past 30 days. Blood samples were collected at study sites and stored at −80°C. Further details about UHS are provided in Supplementary Methods. The study was approved by the Committee on Human Subjects Research at the University of California, San Francisco and the Institutional Review Board of the National Cancer Institute.
Methods used to determine status for HBV, HCV, and human immunodeficiency virus (HIV) infections have been described previously [12] (Supplementary Methods). Participants were tested for anti-HBc and HBsAg; anti-HBc-positive individuals were considered to have been infected with HBV and HBsAgpositive individuals were considered to have "active infection. " Subjects who were negative for anti-HBc and HBsAg, but positive for anti-HBsAg were considered to have serological evidence for HBV vaccination. Subjects who were anti-HCVpositive were considered to have been infected with HCV and tested for HCV RNA. Subjects with a positive HCV RNA result were considered "chronically infected with HCV, " while those with a negative result were considered to have "resolved HCV infection. " Participants were considered HIV-infected if they tested positive for antibodies to HIV-1.
In the present study, specimens from HBsAg-positive participants were tested by HDV Q-MAC. Detailed methods for the assay are provided in Supplementary Methods. As previously described [10] , the assay was constructed on noncontinuous, nanostructured plasmonic gold slides with enhanced near-infrared fluorescence detection. A microarray printing robot was used to place recombinant full-length HDV small delta antigen on the slides. Slides were blocked with fetal bovine serum (FBS), washed with phosphate-buffered saline, and 1 μL of sample (diluted to 50 μL with FBS) was applied to each well. Slides were washed with phosphate-buffered saline and IRDye800-labeled donkey antihuman IgG (diluted 1:1000 in FBS solution) was applied for 1 hour followed by further washing and drying. Slides were then scanned using a Licor Odyssey instrument and the fluorescent intensity measured.
All HBsAg-positive specimens were also tested with an HDV western blot assay and specimens that were positive by western blot were assayed for HDV RNA levels by one-step RT-PCR as described elsewhere [10] . We examined previously defined Q-MAC assay cutoffs for predicting anti-HDV positivity (0.164 fluorescence intensity units) and for predicting HDV RNA positivity (1.659 units) [10] . Samples from participants with active infection who had sufficient remaining serum amount (n = 70) were also tested for HBV DNA levels (Qiagen, Hilden, Germany).
HDV replication requires HBsAg, therefore, we assumed that individuals who tested negative for HBsAg were negative for hepatitis D viremia. On that basis, we calculated the prevalence of viremia among UHS participants overall and in the subset of participants who were anti-HBc-positive. We fitted a logistic regression model to determine the association between risk factors and HDV infection as measured by the adjusted odds ratio (aOR), as well as the corresponding 95% confidence interval (CI) and P value. Finally, we evaluated the relationship between HDV RNA, HBV DNA, and HCV RNA levels among people with active HBV infection.
RESULTS

Study Population
The characteristics of the UHS participants are shown in Supplementary Table 1. Median age at study visit was 45 years, median age at first drug use was 19 years, and median duration of injection drug use at study visit was 24 years. Most participants were men (71%) and 49.5% were African American. Regarding HBV infection, 1764 (76.8%) were anti-HBc-positive, among whom 73 (3.2% of total) had active HBV infection. Chronic and resolved HCV infection was present in 1717 (74.8%) and 375 (16.3%) of participants, respectively. HIV prevalence was 11.9%.
HDV Q-MAC Testing
HDV Q-MAC testing was conducted among the 73 HBsAgpositive participants, with replicate testing performed on samples from 8 subjects. Based on the Q-MAC fluorescence intensity cutoff for anti-HDV positivity (≥ 0.164 units) [10] , all replicates yielded concordant results (4 positive, 4 negative). Results for western blot testing were fully consistent with the Q-MAC results; therefore, HDV Q-MAC yielded a sensitivity and specificity of 100% compared to western blot (Figure 1) .
All 16 specimens that met the previously defined Q-MAC threshold for predicting HDV RNA positivity (≥1.659 units) [10] , were positive for HDV RNA, as were 10 samples with Q-MAC values between 0.164 and 1.659 units (Figure 1,  Supplementary Figure 1) . Therefore, in UHS, the Q-MAC threshold of 1.659 units yielded 61.5% sensitivity and 100% specificity for HDV viremia. Lowering the HDV RNA cutoff value to 0.164 would have yielded 100% sensitivity for predicting HDV RNA positivity.
Prevalence of HDV Viremia
The prevalence of hepatitis D viremia (as reflected by HDV RNA) was 1.1% (26/2296) in all participants, 1.5% (26/1764) in those who had been infected with HBV (anti-HBc-positive), and 35.6% (26/73) among those with active HBV infection (Supplementary Table 2 ). Prevalence did not differ by age at study visit, gender, or race, either overall or in subgroups defined by HBV infection status. However, among those with active HBV infection, higher HDV prevalence was observed with increasing duration of drug use (P trend = 0.02). There was no association between HIV infection status and HDV prevalence. Among anti-HBc-positive PWID, those with resolved HCV infection were approximately 8-fold more likely to have HDV infection compared to chronic HCV infection (5.1% vs 0.6%, respectively; P < .0001); among actively infected individuals that difference was approximately 2-fold (45.7% vs 25.0%; P = .08).
Relationship Between HDV, HBV, and HCV
Using multivariable logistic regression to explore the relationship between chronic hepatitis C and hepatitis D viremia among the individuals who were anti-HBc-positive, individuals with resolved HCV infection were approximately 10-times more likely to be infected with HDV (aOR, 9.80; 95% CI, 4.13-23.19; P < .0001) than those with chronic HCV infection (Supplementary Table 3 ). No other predictors were associated with HDV infection; however, statistical comparisons were limited by sparse data.
We compared the characteristics of the 73 participants with active HBV infection by whether they tested positive or negative for HDV RNA (Supplementary Table 4 ). Individuals with HDV viremia had longer duration of drug use (median, 27.5 vs 22 years; P = .03) and tended to be older (median, 45.7 vs 41.6 years; P = .13), but the groups did not differ by gender or race.
We examined relationships between HDV RNA, HBV DNA, and HCV RNA among participants with active HBV infection. HDV RNA levels were higher in individuals who were positive for HBV DNA; however, that difference did not approach statistical significance (P = .29) (Figure 2A ). HDV RNA levels were higher in those with resolved compared to chronic HCV infection (median [log 10 IU/mL], 4.79 vs 3.00, respectively; P = .03) ( Figure 2B ). HCV RNA levels tended to be lower among HDVinfected compared with HDV-uninfected individuals (median [log 10 IU/mL], 5.44 vs 6.60; P = .21). Only 9 subjects were infected with both HDV and HCV, which limited the statistical power for analyzing the correlation between HDV RNA and HCV RNA levels (Pearson's correlation coefficient = −0.23; P = .55). The relationship between absolute values of HBV DNA and HDV RNA by presence or absence of HCV RNA is depicted in Supplementary Figure 2 .
We also examined HBV DNA levels in the context of HCV and HDV infections ( Figure 2C ). Markedly higher HBV DNA levels were found among individuals who were negative for both HCV RNA and HDV RNA compared to those with chronic HCV alone (P = .0003), chronic HDV alone (P < .0001), or both chronic HCV and chronic HDV (P = .001). HBV DNA levels did not differ among those last 3 groups (P > .50, all comparisons).
Discussion
In this study of PWID, over a third of participants who were positive for HBsAg also had chronic hepatitis D. Methodologic differences limit comparison of our results to findings from previous studies that examined anti-HDV prevalence [5, 6, 13, 14] ; however, our study provides additional evidence that HDV infection is common among HBV-infected PWID in the United States.
The novel HDV Q-MAC assay performed well in this population. Regarding anti-HDV status, both the sensitivity and the specificity were 100% compared to HDV western blot. Furthermore, although Q-MAC measures HDV antibody response, the assay also yielded 100% specificity for predicting hepatitis D viremia (based on previously proposed higher threshold of fluorescence intensity). The proposed cutoffs for this promising assay [10] must be evaluated in a wide range of populations. However, results to date suggest an algorithm might be developed whereby values <0.164 units are considered antibody negative, values of 0.165-1.658 are considered antibody positive/RNA indeterminate, and values ≥1.659 units are considered positive for both anti-HDV and RNA. That approach could allow efficient determination of HDV antibody and RNA status with limited testing for HDV RNA (and no western blot testing).
Viral interaction patterns in the setting of triple hepatitis virus infections are complex. We found that individuals with chronic hepatitis C were much less likely to have HDV viremia and, if HDV RNA was present, the level tended to be lower than among individuals with resolved HCV infection. We also observed lower HBV DNA levels among people with either chronic hepatitis C or chronic hepatitis D. Our study was cross-sectional; therefore, we could not examine the timing of viral acquisition. However, these relationships could have implications for antiviral treatment of chronic hepatitis C. "Interferon-free" HCV regimens based on direct-acting antiviral agents (DAAs) lack the suppressive effect of interferon-α on HBV and HDV. HBV reactivation with fulminant hepatitis has been reported in the context of DAA treatment of HCV and it is possible that poorer control of HDV infection has contributed to some of these cases [15] .
Specimens for this study were collected between 1998 and 2000. Injection practices, prevalence of hepatitis virus infections, and HBV vaccination rates may change over time; however, our results are broadly consistent with results based on anti-HDV testing in the ALIVE cohort of PWID during 2 periods (1988-1989 and 2005-2006) [9] . Given the growing problem of injection drug use in the United States, contemporary data on HDV prevalence among PWID from a wide range of geographic areas are needed.
In conclusion, hepatitis D viremia was common in PWID with active HBV infection, but uncommon overall due to a low prevalence of active HBV infection. The HDV Q-MAC assay demonstrated excellent performance characteristics in this US cohort and could form the backbone of an efficient algorithm for determining HDV antibody and viremia status. We observed lower HDV RNA levels in individuals with chronic HCV infection, consistent with suppression of viral replication in those with triple hepatitis infections. Future research should examine the impact of therapeutic clearance of HCV infection among individuals who are also chronically infected with HBV and HDV.
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